BCN PEPTIDES
BCN PEPTIDES
3 Projects, page 1 of 1
Open Access Mandate for Publications assignment_turned_in Project2020 - 2022Partners:APEPTICO, RTDS Association (RTDS), OPIS SRL, BCN PEPTIDES, LMUAPEPTICO,RTDS Association (RTDS),OPIS SRL,BCN PEPTIDES,LMUFunder: European Commission Project Code: 101003595Overall Budget: 1,626,020 EURFunder Contribution: 1,626,020 EURClinical features of patients infected with the 2019-nCoV have revealed that these patients suffer from severe respiratory failure, and presence of a life-threatening pulmonary oedema (PPO). Approx. 30% of 2019-nCoV-patients further develop life-threatening Acute Respiratory Distress Syndrome (ARDS). Mortality rate of these patients is very high. Initiator and Scientific Coordinator of the project, APEPTICO, is a SME biotechnology company (EMEA/SME/012/09) developing peptide-based products targeting life-threatening pulmonary diseases, including oedematous respiratory failure, acute lung injury, primary graft dysfunction, high altitude pulmonary oedema and PHA type 1. APEPTICO’s lead-compound Solnatide (INN) has been designed for the therapeutic treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and various forms of life-threatening Pulmonary Oedema (PPO). Orally inhaled Solnatide has delivered clinical proof-of-concept in one Phase I, and in two Phase II clinical studies (EUDRACT No. 2011-000223-33, 2012-001863-64, 2013-000716-21). Today, no medicine has been approved for the therapeutic treatment of Pulmonary Permeability Oedema and ARDS. Currently, Solnatide is subject to a Phase IIB trial (EUDRACT No. 2017-003855-47) for the “treatment of pulmonary permeability oedema in patients with ARDS”. The Phase IIB clinical trial has been approved by the German and the Austrian Competent Authorities, as well by Ethic Committees of leading Medical University Hospitals in Germany as well Austria. Most recently, APEPTICO has entered into a partnership with HAISCO Pharmaceutical Group in Chengdu, Sichuan, P.R. China. HAISCO has access to core areas and leading Medical University Hospitals in the P.R. China. Accordingly, APEPTICO proposes to immediately apply the Solnatide IMP for the treatment of patients infected with the 2019-nCoV and to demonstrate safety, tolerability and clinical efficacy of Solnatide IMP in 2019-nCoV patients. The overall project coordination and external communications is by RTDS Association (www.rtds-group.com/association)
more_vert Open Access Mandate for Publications assignment_turned_in Project2012 - 2016Partners:Aston University, University of Liverpool, AP-HP, UNITO, ICS +13 partnersAston University,University of Liverpool,AP-HP,UNITO,ICS,UNIPD,BCN PEPTIDES,FVIB,Moorfields Eye Hospital NHS Foundation Trust,IDF EUROPE,GHNHSFT,Vita-Salute San Raffaele University,AIBILI ASSOCIACAO PARA INVESTIGACAO BIOMEDICA E INNOVACAO EM LUZ E IMAGEM,CAIBER,CSIC,VHIR,SDU,University of UlmFunder: European Commission Project Code: 278040more_vert Open Access Mandate for Publications assignment_turned_in Project2012 - 2017Partners:UNIGE, Technion – Israel Institute of Technology, ICS, IKT/CIMT, University of Glasgow +8 partnersUNIGE,Technion – Israel Institute of Technology,ICS,IKT/CIMT,University of Glasgow,University of Tübingen,BioNTech,University Hospital Heidelberg,University of Southampton,LUMC,Immatics Biotechnologies (Germany),REGIONH,BCN PEPTIDESFunder: European Commission Project Code: 305061more_vert